Book Chapter10.1002/9783527651085.CH14
Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure‐Based Drug Design
Srikanth Venkatraman,Andrew Prongay,Njoroge George F +2 more
- 18 Dec 2012
- pp 343-363
2
About: The article was published on 18 Dec 2012. The article focuses on the topics: Narlaprevir & Boceprevir.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?
Simona Di Martino,Giovanna Li Petri,Maria de Lurdes Pereira Rosa +2 more
TL;DR: HCV NS3/4A peptidomimetic inhibitors have revolutionized treatment, achieving high cure rates and addressing the issue of resistance. However, ongoing research is needed to further optimize and develop novel therapies to combat the evolving viral landscape.
Synthesis of [c]‐Fused Bicyclic Proline Analogues
TL;DR: An overview of synthetic methods developed to build [c]-fused bicyclic proline analogues is presented, focusing on the preparation of azabicycles that bear a carbocyclic ring fused to the [c] face of the pyrrolidine unit.
References
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
TL;DR: A random-primed complementary DNA library was constructed from plasma containing the uncharacterized non-A, non-B hepatitis agent and screened with serum from a patient diagnosed with NANBH, showing consistent with the agent being similar to the togaviridae or flaviviridae.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
6.5K
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
George Kuo,Q L Choo,Harvey J. Alter,G.L. Gitnick,Allan G. Redeker,Robert H. Purcell,Tatsuo Miyamura,Jules L. Dienstag,M.J. Alter,Cladd E. Stevens,Gary E. Tegtmeier,Ferruccio Bonino,Massimo Colombo,W.-S. Lee,C. Kuo,K. Berger,Jeffrey R. Shuster,Lacy Rasco Overby,Daniel W. Bradley,Michael Houghton +19 more
TL;DR: Assays of ten blood transfusions in the United States that resulted in chronic NANBH revealed that there was at least one positive blood donor in nine of these cases and that all ten recipients seroconverted during their illnesses.
3.3K
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
TL;DR: This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed molecular studies ofHCV and the development of antiviral drugs.
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
TL;DR: The addition of boceprevir to standard therapy with peginterferon–ribavirin, as com pared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Related Papers (5)
Kian Bichoupan,Neeta Tandon,Valérie Martel-Laferrière,Neal Patel,David H. Sachs,Michel Ng,Emily A. Schonfeld,Alexis Pappas,James F. Crismale,A. Stivala,Viktoriya Khaitova,Donald Gardenier,Michael D. Linderman,William Olson,Ponni V. Perumalswami,Thomas D. Schiano,Joseph A. Odin,Lawrence U. Liu,Douglas T. Dieterich,Andrea D. Branch +19 more